The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.
Daniel J. George, MD
Advertisement
Articles by Daniel J. George, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose
3
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
4
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
5